Reaction

Conjunctival Haemorrhage reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,769 reports · 86 co-occurring drugs

As of the last recalculation, Conjunctival Haemorrhage appears in 3,769 FAERS reports alongside 86 co-occurring drug terms. The strongest observed disproportionality signal is RANIBIZUMAB (PRR 17.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ranibizumab	82	17.4	17.5
Aflibercept	94	17.0	17.1
Imatinib Mesylate	56	11.2	11.3
Faricimab	16	10.9	11.0
Itraconazole	20	9.5	9.5
Romiplostim	25	9.2	9.2
Warfarin Sodium	66	8.0	8.0
Imatinib	25	7.9	7.9
Brinzolamide	12	7.7	7.7
Prednisolone Acetate	14	7.5	7.5
Lifitegrast	19	6.4	6.5
Clopidogrel Bisulfate	116	6.4	6.4
Warfarin	139	6.2	6.2
Brimonidine Tartrate	20	6.2	6.2
Desloratadine	12	6.2	6.2
Colchicine	28	5.9	5.9
Rivaroxaban	212	5.9	5.9
Dabigatran Etexilate	78	5.6	5.6
Dorzolamide Hydrochloride And Timolol Maleate	8	5.6	5.6
Bosutinib	9	5.5	5.5
Timolol	12	5.5	5.5
Dronedarone	10	5.4	5.4
Tobramycin Sulfate	12	5.4	5.4
Phytonadione	8	5.2	5.2
Triamcinolone Acetonide Ointment Usp, 0.05%	22	5.2	5.2
Dabigatran Etexilate Mesylate	67	5.2	5.2
Travoprost	8	5.1	5.1
Tobramycin Solution	11	5.1	5.1
Timolol Maleate	9	5.0	5.0
Prasugrel Hydrochloride	9	4.9	4.9
Triamcinolone Acetonide	26	4.7	4.7
Clopidogrel	159	4.6	4.6
Botulinum Toxin Type A	10	4.5	4.5
Miconazole Nitrate	7	4.4	4.4
Moxifloxacin Hydrochloride	16	4.4	4.4
Eltrombopag Olamine	18	4.3	4.3
Bumetanide	20	4.2	4.2
Avapritinib	9	4.1	4.1
Bevacizumab	90	4.1	4.1
Clotrimazole	9	4.1	4.1
Nilotinib	20	3.8	3.8
Ibrutinib	52	3.6	3.6
Latanoprost	32	3.5	3.5
Sunitinib Malate	25	3.5	3.5
Apixaban	42	3.5	3.5
Nebivolol	10	3.5	3.5
Cefepime	9	3.5	3.5
Cefepime Hydrochloride	10	3.4	3.4
Melphalan	14	3.4	3.4
Posaconazole	10	3.4	3.4
Hydroxyurea	13	3.4	3.4
Pravastatin Sodium	12	3.4	3.4
Cenegermin-Bkbj	7	3.2	3.2
Azelastine	10	3.1	3.1
Bimatoprost	16	3.1	3.1
Nevirapine	5	3.1	3.1
Posaconazole Delayed-Release	6	3.0	3.0
Alteplase	8	2.9	2.9
Dexlansoprazole	22	2.9	2.9
Tobramycin	12	2.8	2.8
Fondaparinux Sodium	4	2.7	2.7
Dasatinib	18	2.7	2.7
Azacitidine	14	2.6	2.6
Micafungin Sodium	4	2.6	2.6
Thalidomide	17	2.6	2.6
Selinexor	4	2.6	2.6
Etoposide	33	2.5	2.5
Azacitidine For	8	2.4	2.4
Polatuzumab Vedotin	4	2.3	2.3
Riociguat	13	2.2	2.2
Crizotinib	5	2.2	2.2
Ticagrelor	12	2.1	2.1
Derma Foam Excel Hand Sanitizer	3	2.1	2.1
Ethanol	3	2.1	2.1
Fremanezumab-Vfrm	4	1.9	1.9
Lapatinib	5	1.8	1.8
Ixazomib	9	1.7	1.7
Sofosbuvir	6	1.7	1.7
Axicabtagene Ciloleucel	3	1.7	1.7
Tafamidis	3	1.4	1.4
Buprenorphine	23	1.4	1.4
Durvalumab	5	1.4	1.4
Emicizumab	3	1.3	1.3
Relugolix	5	1.2	1.2
Minoxidil Foam 5% (Womens)	5	0.8	0.8
Nirmatrelvir And Ritonavir	7	0.7	0.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.